Search results
Results from the WOW.Com Content Network
The COVID-19 pandemic in New South Wales, Australia was part of the worldwide pandemic of the coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 . The first confirmed case in New South Wales was identified on 19 January 2020 in Sydney where three travellers returning from Wuhan , Hubei , China, tested positive ...
COVID-19: Shionogi: 3C-like protease inhibitor Entecavir: HIV NRTI 2005 Etravirine (Intelence) [8] HIV NNRTI 2008 Famciclovir: Herpes Zoster: Guanosine analogue 1994 Fomivirsen: AIDS Anti-sense oligonucleotide: Anti-sense FDA-licensed in 1998; Withdrawn in EU (2002), US (2006) Fosamprenavir: HIV ViiV Healthcare: Amprenavir pro-drug: 2003 (FDA ...
1828–1829 New South Wales smallpox epidemic 1828–1829 New South Wales, Australia Smallpox: 19,000 [136] [137] Groningen epidemic: 1829 Netherlands Malaria: 2,800 [138] 1829–1833 Pacific Northwest malaria epidemic 1829–1833 Pacific Northwest, United States Malaria, possibly other diseases too 150,000 [139] [140] 1829–1835 Iran plague ...
This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. Brand names and generic names are differentiated by capitalizing brand names. See also the list of the top 100 bestselling branded drugs, ranked by sales.
For premium support please call: 800-290-4726 more ways to reach us
In New South Wales, poisons are proclaimed in the Poisons List by the Poisons Advisory Committee, under the authority of the Poisons and Therapeutic Goods Act 1966 (NSW). NSW legislation refers to S2 as "medicinal poisons", S3 as "potent substances", S4 as "restricted substances" and S8 as "drugs of addiction".
The Biden administration on Wednesday said it will impose inflation penalties on 64 prescription drugs for the third quarter of this year, lowering costs for certain older Americans enrolled in ...
This registry based, multi-center, multi-country data provide provisional support for the use of ECMO for COVID-19 associated acute hypoxemic respiratory failure. Given that this is a complex technology that can be resource intense, guidelines exist for the use of ECMO during the COVID-19 pandemic. [85] [86] [87]